Business
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant Two additional patients from Phase 2a clinical trials of imdusiran achieve functional cure Milestone payment received under Alnylam LNP license for product candidate to treat hepatocellular carcinoma (HCC) WARMINSTER, Pa., March 23, 202
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"image","alt":"Arbutus Biopharma Corporation","displaySize":"","headline":null,"caption":"Arbutus Biopharma Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":127,"url":"https://media.zenfs.com/en/globenewswire.com/1cbb6acd2ea052e46399d6c510e021f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2H62JXS1Ed1gs5h6nJ08kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3OA--/https://media.zenfs.com/en/globenewswire.com/1cbb6acd2ea052e46399d6c510e021f8","width":300,"height":127}},"lazy":false},{"type":"text","content":"Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025","length":109,"tagName":"p"},{"type":"text","content":"$2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant","length":153,"tagName":"p"},{"type":"text","content":"Two additional patients from Phase 2a clinical trials of imdusiran achieve functional cure","length":90,"tagName":"p"},{"type":"text","content":"Milestone payment received under Alnylam LNP license for product candidate to treat hepatocellular carcinoma (HCC)","length":114,"tagName":"p"},{"type":"text","content":"WARMINSTER, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported fourth quarter and year end 2025 financial results and provided a corporate update.","length":299,"tagName":"p"},{"type":"text","content":"“We delivered another strong quarter, maintaining a disciplined approach to capital allocation and a continued focus on maximizing our cash runway,” said Lindsay Androski, President and CEO of Arbutus. “I am thrilled to announce that two additional patients from our Phase 2a trials of imdusiran have achieved functional cure in chronic hepatitis B (“cHBV”), and am pleased with our team’s continuing progress on our cHBV programs.”","length":432,"tagName":"p"},{"type":"text","content":"LNP Litigation","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"On March 3, 2026, Arbutus, along with its exclusive licensee, Genevant Sciences (“Genevant”), entered into a settlement agreement to resolve all global patent infringement litigation and patent r...